The 10 priciest 340B medications

In 2023, the top 10 drugs purchased under the 340B Drug Pricing Program accounted for roughly one-third of the program's total spending, according to a Health Resources and Services Administration news release. 

Here is a breakdown of the 10 priciest 340B medications: 

1. Keytruda (oncology): $6.91 billion in sales 
2. Biktarvy (HIV): $3.58 billion 
3. Opdivo (oncology): $1.95 billion 
4. Darzalex Faspro (oncology): $1.89 billion 
5. Ocrevus (oncology): $1.85 billion 
6. Trikafta (cystic fibrosis): $1.82 billion 
7. Humira (CF) Pen (immunology): $998.8 million
8. Descovy (HIV): $969.5 million 
9. Entyvio (immunology): $949.7 million 
10. Durvalumab (oncology): $889.6 million